Journal article · Research (general)← The news desk

✦ The Dispatch

Teprotumumab for dysthyroid optic neuropathy: a systematic review and pooled analysis of 81 eyes evaluating outcomes, safety, and durability

A dispatch from PubMed — filed

To review the efficacy, safety, and durability of teprotumumab (TEP) in the treatment of dysthyroid optic neuropathy (DON).

Continue reading at PubMed

✦ The floor

Discussion

Signed responses from readers of the wire.

✦ Clinical Takeaway ✦

No actionable change for audiologists — this systematic review concerns an ophthalmologic condition with minimal direct hearing-health relevance.

✦ Why It Matters ✦

Teprotumumab has a known side-effect profile that includes hearing-related adverse events (such as sensorineural hearing loss and tinnitus), so audiologists may encounter patients on this drug who need hearing monitoring.

✦ Key Points ✦
  1. 01Systematic review and pooled analysis of 81 eyes treated with teprotumumab for dysthyroid optic neuropathy.
  2. 02Primary focus is ophthalmologic efficacy, safety, and treatment durability — not audiology.
  3. 03Teprotumumab is known from prior literature to carry a risk of hearing-related adverse events (ototoxicity).
  4. 04No primary hearing outcome data are reported in this study.
  5. 05Audiologists should be aware that patients on teprotumumab may warrant hearing monitoring.
✦ Claims & Evidence ✦

Teprotumumab is effective for treating dysthyroid optic neuropathy based on pooled analysis of 81 eyes.

studypartially supported

Teprotumumab demonstrates acceptable safety and durable outcomes for dysthyroid optic neuropathy.

studypartially supported
✦ Research metadata ✦
PMID
43046497
DOI
10.1080/01676830.2026.2760368.
Journal
Journal of Neuro-Ophthalmology
Publication type
meta_analysis
Evidence level
1a
Sample size
81
Population
Patients with dysthyroid optic neuropathy treated with teprotumumab (81 eyes)
Intervention
Teprotumumab (IGF-1R inhibitor) for dysthyroid optic neuropathy

Primary outcomes

Visual outcomes (efficacy); Safety profile; Durability of treatment response

✦ Related stories ✦